Dr. Chen Liang (Ph.D.) CEO & Co-Founder
Dr. Chen has rich experience in drug development and biotechnology. He had led 5 biosimilar and innovative large molecules to IND stage in 3 years.
Dr. Chen was in charge of downstream process development and Manufacturing Director of Favrille in US; he was involved in development of cGMP manufacturing workshop, and led product to clinical trial phase 3. He also was in charge of biologics development process and Manufacturing Director of Synageva BioPharma, and was responsible for development of cytokine, monoclonal antibody (Biosimilar) and orphan drug, and led 5 biologics to clinical trial phase 1-3.
Dr. Chen holds Ph.D. of biochemistry of University of Georgia.
Dr. Wang Yong Gang (Ph.D.) Vice-President
Dr. Wang has more than ten years’ experience in biologics development and management, and worked on technology and project research and management for Tiens Group, YinFeng Biological Group, CK Life Sciences.
Dr. Wang was responsible for and led Polynoma, an innovative biologics project, from clinical trial phase 2 to phase 3 of US FDA, and led S4 (New Drug Class 1), a national project “great innovative drug”, to acquire supplementary clinical approval and to NDA stage.
Dr. Wang is a Ph.D. from co-nurturing program by Bioreactor State Key Laboratory of South China University of Technology and Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences.